Recently, the catalytic FAK inhibitor defactinib was granted accelerated approval by the FDA for the treatment of KRAS-mutant low grade serious ovarian cancer (LGSOC) in combination with the RAF/MEK clamp avutometinib [73]. This evidence concerns the gene MAP2K7 and ovarian carcinoma.